psychedelics investing Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
psychedelics investing Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
psychedelics investing Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
psychedelics investing Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
psychedelics investing New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
psychedelics investing Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
psychedelics investing Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
psychedelics investing Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression Awareness Day
psychedelics investing Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia
psychedelics investing Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
psychedelics investing Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
psychedelics investing Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver
Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement
